Clinical Trial Update: Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Combigan BID to Simbrinza TID in glaucoma and ocular hypertension; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• Combigan (brimonidine tartrate and timolol maleate)
• Simbrinza (brinzolamide/brimonidine)

Snippet

Sponsor: Cornerstone Health Care, PA | Conditions: Glaucoma, Ocular Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2018-10-24